Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function

Pfizer Inc.Pfizer announced that post-stroke or mini-stroke patients treated with Lipitor® (atorvastatin calcium) Tablets 80 mg had stabilization or improvement in kidney function. These results were demonstrated in patients with or without chronic kidney disease, metabolic syndrome or type 2 diabetes. This post-hoc analysis of the landmark Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study, was presented at the Annual Scientific Sessions of the American Heart Association.

About 700,000 Americans and 1.1 million Europeans suffer from a stroke or mini-stroke annually. Data from the SPARCL study show that stroke patients with type 2 diabetes, metabolic syndrome or chronic kidney disease are at increased risk of additional cardiovascular events, compared to patients without these conditions.

Analysis of Changes in Kidney Function in the SPARCL study
In this new post-hoc analysis (planned after the study closed) of the SPARCL study, kidney function was evaluated by estimated glomerular filtration rate (eGFR, mL/min/1.73m2), a standard test to measure how well the kidneys function.

Post-stroke or mini-stroke patients without chronic kidney disease, with chronic kidney disease and with metabolic syndrome treated with Lipitor 80 mg had significantly improved kidney function compared to placebo.

In post-stroke or mini-stroke patients with type 2 diabetes, those treated with Lipitor demonstrated stabilized kidney function, while patients receiving placebo had significantly declined kidney function during the trial.

"These results are especially significant for post-stroke diabetic patients because they are more likely to develop progressive kidney disease," said Dr. Vito Campese, chief of the division of nephrology/hypertension at the University of Southern California. "With Lipitor we were able to stabilize patients’ kidney function, and given the established relationship between progressive kidney disease and cardiovascular outcome, this may contribute to reducing cardiovascular events. These results are similar to findings from the Treating to New Targets study which found that patients with coronary heart disease treated with Lipitor had stabilized and even improved kidney function."

Post-stroke or mini-stroke patients treated with Lipitor 80 mg had:

  • Significantly improved kidney function compared to placebo in those 2,671 patients without chronic kidney disease (change in eGFR during the trial 2.22 vs. 0.22 mL/min/1.73m2, p<0.0001)
  • Significantly improved kidney function compared to placebo in those 1,315 patients with chronic kidney disease (change in eGFR during the trial of 3.15 vs. 1.82 mL/min/1.73m2,p=0.017)
  • Significantly improved kidney function, measured as change in estimated glomerular filtration rate, compared to placebo in those 593 patients with metabolic syndrome (change in eGFR during the trial of 2.39 vs. 0.24 mL/min/1.73m2, respectively p=0.012)
  • Stabilized kidney function compared to placebo in those 730 patients with type 2 diabetes (change in eGFR of -0.735 vs. -4.016 mL/min/1.73m2, p<0.001).

Additional Analysis of Cardiovascular Outcomes in Patients with Chronic Kidney Disease
In the SPARCL study, patients with chronic kidney disease had higher risk of stroke (27 percent) or major coronary events (70 percent) compared to patients without chronic kidney disease.

  • In patients with chronic kidney disease, Lipitor 80 mg significantly reduced the risk of major coronary events (including cardiovascular death, non-fatal heart attack, resuscitated cardiac arrest) by 39 percent compared to placebo, however there was no difference in the risk of stroke compared to placebo

About the SPARCL Study
The SPARCL study (n=4,731), published in the New England Journal of Medicine in 2006, is the only study to date evaluating the benefits of a statin solely in patients with a prior stroke or mini-stroke. Lipitor 80 mg reduced the risk of an additional stroke by 16 percent and major coronary events by 35 percent compared with placebo.

In a post-hoc analysis of the SPARCL trial, there was a higher incidence of hemorrhagic stroke in patients taking Lipitor 80 mg compared with patients taking placebo. Patients with prior hemorrhagic stroke at study entry appeared to be at an increased risk of hemorrhagic stroke.

In SPARCL, Lipitor was well-tolerated. The rate of side effects such as elevated liver enzymes, muscle weakness or rhabdomyolysis were low and consistent with the known safety profile.

About Stroke, Kidney Disease and Cardiovascular Disease
Cardiovascular disease is the number one cause of death globally and is projected to remain the leading cause of death. Stroke is the third leading cause of death and the leading cause of adult disability in the United States and industrialized European nations. About 700,000 Americans and 1.1 million Europeans suffer from a stroke or mini-stroke annually. The World Health Organization estimates that 15 million people each year suffer strokes and 5 million are left permanently disabled.

It is estimated that 4.5 million people in Europe have chronic renal disorders, with kidney diseases representing a leading cause of mortality. Chronic kidney disease has been recognized as an important risk factor for cardiovascular disease. Various illnesses may lead to chronic kidney disease, including high blood pressure and diabetes, the number-one cause of kidney failure.

About Lipitor
Lipitor is the most extensively studied and most prescribed cholesterol-lowering therapy in the world, with nearly 144 million patient-years of experience. Lipitor is supported by an extensive clinical trial program involving more than 400 ongoing and completed trials with more than 80,000 patients.

For additional product information, visit www.Lipitor.com.

Most Popular Now

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Pfizer and BioNTech announce data from preclinical…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based v...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Sinovac reports preliminary Phase I/II results of …

Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 vaccin...

COVID-19 study links strict social distancing to m…

Using public transportation, visiting a place of worship, or otherwise traveling from the home is associated with a significantly higher likelihood of testing positive wi...

CureVac expected to receive up to 252 million euro…

CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...